Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study

By sjmartinez • January 18, 2024

Aggarwal R, Schessl J, Charles-Schoeman C, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis CV, Schiopu E, Vencovský J, Beckmann I, Clodi E, Levine T; ProDERM investigators. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024 Jan 17;26(1):27. doi: 10.1186/s13075-023-03232-2. PMID: 38233885.

Tags: Dermatomyositis, Intravenous immunoglobulin, Myositis, Publications, Rheumatology, safety, Tolerability

Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy

Li YR, Nan H, Liu Z, Fang Y, Zhu Y, Lyu Z, Shao Z, Zhu E, Zhang B, Yang Y, Shen X, Chen Y, Hsiai[...]

JPEN Journal Club 99. ICEMAN analyses

Koretz RL. JPEN Journal Club 99. ICEMAN analyses. JPEN J Parenter Enteral Nutr. 2026 Mar 17. doi: 10.1002/jpen.70072. Epub ahead of print. PMID: 41846318.

A Double-blind Randomized Trial of Oral Chlorhexidine Gluconate for Treatment of Oral Staphylococcus aureus Colonization in Healthy Children

Liu L, Launer B, Flores E, Tchakalian G, Kreiswirth B, Bolaris M, Kim T, Young KD, Miller LG. A Double-blind Randomized Trial of Oral Chlorhexidine[...]